A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Journal: Cell

Published: 2018-11-01

DOI: 10.1016/j.cell.2018.09.006

Affiliations: 18

Authors: 52

Go to article
Institutions FC
Department of Medical Oncology, DFCI, United States of America (USA) 0.35
Broad Institute of MIT and Harvard, United States of America (USA) 0.17
Cancer Center, MGH, United States of America (USA) 0.13
Harvard Medical School Laboratory of Systems Pharmacology (HMS LSP), United States of America (USA) 0.07
Department of Cancer Immunology and Virology, DFCI, United States of America (USA) 0.06
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, United States of America (USA) 0.06
Joint Center for Cancer Precision Medicine, United States of America (USA) 0.05
Molecular and Cellular Oncogenesis Program, The Wistar Institute, United States of America (USA) 0.02
The Wistar Institute Melanoma Research Center, United States of America (USA) 0.02
Clinic for Dermatology, UDE, Germany 0.02
DKTK Partner Site Essen/Düsseldorf, Germany 0.02
Celsius Therapeutics, United States of America (USA) 0.01
Division of Surgical Oncology, BWH, United States of America (USA) 0.01
Ludwig Center at Harvard Medical School, United States of America (USA) 0.01
Department of Dermatology, Venerology and Allergology, JMU, Germany 0.01
Ludwig Center at MIT, United States of America (USA) 0.01
MIT Department of Biology, United States of America (USA) 0.01
Howard Hughes Medical Institute (HHMI), United States of America (USA) 0

Return